ID Week

Results from the Pivotal ADAPT-PO study were reported.

Results show medication provides therapeutic response for Candida.

In an effort to expand serotype coverage beyond 13, a 20-valent pneumococcal conjugate vaccine, PCV20, is currently in development.

Overall, 88% of participants who received long-acting therapy preferred CAB LA+RPV LA compared with oral treatment.

The results support B/F/TAF as a switch option for Black Americans who are virologically suppressed, including individuals with a history of treatment failure or pre-existing resistance.

How has the COVID-19 pandemic affected clinical trial site restrictions, drug delivery, dosing, patient monitoring, and follow-up?

New data presented at IDWeek showed more than half observed households with a COVID-19 case reported a secondary infection, oftentimes within 3 days.

Phase 1 data and a history of benefit for worsening respiratory infections show promise for the therapy.

New head-to-head phase 3 data show a promising potential new HBV vaccine may join the market in the near future.

In a large nursing home study, asymptomatic and symptomatic residents were found to carry similar viral loads.

New data show ADA-recommended oral care for inpatients is associated with an 85% reduction in NVHAP infections at an 800-bed medical center over a year.

A study looked at weight gain when changing therapy regimens.

Sulopenem was superior to ciprofloxacin for the treatment of uncomplicated urinary tract infections.

In a phase 1/2 randomized clinical trial, GlaxoSmithKline’s RSVPreF3 vaccine elicits a response.

The composition of the gut microbiome is easily disrupted by antibiotics, leaving the host susceptible to further infection or other disturbance of gut flora that can lead to both short- and long-term deleterious effects.

A vaccine developer joins for a firsthand discussion on the development, research, and distribution process.

In results of a national survey, investigators pieced together a look at the psychological toll of the pandemic on physicians and identified the biggest stressors.

The CovidIQ tool successfully predicted a COVID-19 spike in Jacksonville, Florida, a full 2 weeks before it was recognized by the Florida Department of Health.

Antimicrobial-resistant infections, in particular those caused by gram-negative pathogens that also produce extended spectrum β-lactamases (ESBL), represent a growing threat across the globe as investigators race to develop novel therapeutics

Andrea L. Cox, MD, PhD, comments on the future of HCV vaccine development efforts in light of the 2019 trial which did not prevent chronic infection.

Andrea L. Cox, MD, PhD, discusses the implications of discovering that an experimental vaccine was not effective at preventing chronic hepatitis C virus.

Daniel B. Chastain, PharmD, BCIDP, AAHIVP, clinical assistant professor at the University of Georgia College of Pharmacy, explains antiretroviral stewardship.

Max Brito, MD, MPH, remarks on the underrepresentation of transgender women in HIV and other sexual health research.

Ryan K. Shields, PharmD, MS, reacts to research presented at IDWeek 2019 on cefiderocol versus high-dose meropenem for patients with nosocomial pneumonia.

A study by Shikha Garg, MD, MPH, and her team with the US Centers for Disease Control and Prevention boosts the evidence base for the benefit of influenza vaccination.

Max Brito, MD, MPH, discusses his presentation from IDWeek 2019 which compared HIV treatment in a community-based model versus a hospital-based model in Chicago.

Erin McCreary, PharmD, BCPS, BCIDP, shares her takeaways from IDWeek 2019.

Angela Campbell, MD, MPH, details a study on influenza vaccine effectiveness in children with respiratory illness.

Pavel Prusakov, PharmD, highlights how he educated pharmacists from South Africa to lead antimicrobial stewardship programs in the NICU with Pablo J. Sánchez, MD, and Debra Goff, PharmD.